

Diaceutics PLC

PDMR Shareholding/Share Incentive Plan and Total Voting Rights

New York, Belfast and London, 1 April 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 30 March 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled on 30 March 2026 by utilising a balance of previously allotted but unallocated Shares held by the UK Trust. The Trust will continue to hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.

As a result, the number of Share Diaceutics has in issue remains unchanged at 84,917,283 Shares. This figure may continue to be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer
 Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
 investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7253 8000

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network[®].

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Susanne Munksted
2	Reason for notification	
a.	Position/Status	Chief Precision Medicine Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTV64	
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")	
c.	Price(s) and volume(s)	Share purchase:	
		Price(s)	Volume(s)
		148.9 p	100
		Conditional share award:	
		Price(s)	Volume(s)
		Nil	100
e.	Date of the transaction	Share purchase and Conditional share award: 30 March 2026	
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market	

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014			
1 Details of the person discharging managerial responsibilities/person closely associated			
a.	Name	Jordan Clark	
2 Reason for notification			
a.	Position/Status	Chief Data Officer	
b.	Initial notification/ Amendment	Initial	
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	Diaceutics PLC	
b.	LEI	213800VEWQBB39ZB8J81	
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTV64	
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")	
c.	Price(s) and volume(s)	Share purchase:	
		Price(s)	Volume(s)

		<table border="1"> <tr> <td>148.9 p</td> <td>100</td> </tr> <tr> <td colspan="2">Matched share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>100</td> </tr> </table>	148.9 p	100	Matched share award:		Price(s)	Volume(s)	Nil	100
148.9 p	100									
Matched share award:										
Price(s)	Volume(s)									
Nil	100									
e.	Date of the transaction	Share purchase and Matched Share award: 30 March 2026								
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market								

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014												
1 Details of the person discharging managerial responsibilities/person closely associated												
a.	Name	Nick Roberts										
2 Reason for notification												
a.	Position/Status	Chief Finance Officer										
b.	Initial notification/ Amendment	Initial										
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor												
a.	Name	Diaceutics PLC										
b.	LEI	213800VEWQBB39ZB8J81										
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted												
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64										
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")										
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 20px;"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>148.9 p</td> <td>100</td> </tr> <tr> <td colspan="2">Matched share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>100</td> </tr> </table>	Price(s)	Volume(s)	148.9 p	100	Matched share award:		Price(s)	Volume(s)	Nil	100
Price(s)	Volume(s)											
148.9 p	100											
Matched share award:												
Price(s)	Volume(s)											
Nil	100											

e.	Date of the transaction	Share purchase and Matched Share award: 30 March 2026
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHKZGGDGMKGVZM